DexCom, Inc. (NASDAQ:DXCM) insider Andrew K. Balo sold 7,825 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $125.00, for a total value of $978,125.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Andrew K. Balo also recently made the following trade(s):
- On Tuesday, March 12th, Andrew K. Balo sold 10,917 shares of DexCom stock. The stock was sold at an average price of $142.79, for a total value of $1,558,838.43.
Shares of DXCM stock opened at $149.84 on Friday. The company has a current ratio of 7.18, a quick ratio of 6.75 and a debt-to-equity ratio of 1.57. The company has a market capitalization of $13.28 billion, a PE ratio of 499.47 and a beta of 0.70. The company has a 50 day moving average of $130.53. DexCom, Inc. has a 1 year low of $92.33 and a 1 year high of $157.50.
Several hedge funds have recently modified their holdings of the stock. Amundi Pioneer Asset Management Inc. grew its stake in shares of DexCom by 11.5% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 202,165 shares of the medical device company’s stock worth $24,078,000 after purchasing an additional 20,913 shares during the last quarter. Allstate Corp bought a new position in DexCom during the first quarter valued at about $247,000. Cerebellum GP LLC boosted its stake in DexCom by 24.2% during the first quarter. Cerebellum GP LLC now owns 2,698 shares of the medical device company’s stock valued at $321,000 after buying an additional 526 shares in the last quarter. Blair William & Co. IL boosted its stake in DexCom by 4.6% during the first quarter. Blair William & Co. IL now owns 1,010,355 shares of the medical device company’s stock valued at $120,333,000 after buying an additional 44,803 shares in the last quarter. Finally, Sit Investment Associates Inc. boosted its stake in DexCom by 46.5% during the first quarter. Sit Investment Associates Inc. now owns 14,500 shares of the medical device company’s stock valued at $1,727,000 after buying an additional 4,600 shares in the last quarter. Institutional investors and hedge funds own 96.41% of the company’s stock.
Several analysts have issued reports on the company. BidaskClub downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine raised DexCom from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 21st. Zacks Investment Research raised DexCom from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a research note on Tuesday, April 30th. Piper Jaffray Companies lifted their price target on DexCom to $173.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Finally, TheStreet cut DexCom from a “c” rating to a “d+” rating in a report on Friday, April 5th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. DexCom presently has a consensus rating of “Buy” and an average price target of $150.65.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: How is a price target determined?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.